ATE437642T1 - Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren - Google Patents

Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren

Info

Publication number
ATE437642T1
ATE437642T1 AT03733426T AT03733426T ATE437642T1 AT E437642 T1 ATE437642 T1 AT E437642T1 AT 03733426 T AT03733426 T AT 03733426T AT 03733426 T AT03733426 T AT 03733426T AT E437642 T1 ATE437642 T1 AT E437642T1
Authority
AT
Austria
Prior art keywords
peptic
treatment
proton pump
pump inhibitors
imidazole derivative
Prior art date
Application number
AT03733426T
Other languages
English (en)
Inventor
Keiji Kamiyama
Hiroshi Banno
Fumihiko Sato
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE437642T1 publication Critical patent/ATE437642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03733426T 2002-06-14 2003-06-13 Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren ATE437642T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002175086 2002-06-14
JP2003041085 2003-02-19
PCT/JP2003/007546 WO2003105845A1 (en) 2002-06-14 2003-06-13 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers

Publications (1)

Publication Number Publication Date
ATE437642T1 true ATE437642T1 (de) 2009-08-15

Family

ID=29738411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03733426T ATE437642T1 (de) 2002-06-14 2003-06-13 Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren

Country Status (19)

Country Link
US (2) US7410981B2 (de)
EP (2) EP1514870A4 (de)
JP (1) JPWO2003106429A1 (de)
KR (1) KR20050009751A (de)
CN (1) CN1678315A (de)
AR (1) AR040221A1 (de)
AT (1) ATE437642T1 (de)
AU (2) AU2003242388A1 (de)
BR (1) BR0311801A (de)
CA (2) CA2489470A1 (de)
DE (1) DE60328603D1 (de)
IL (1) IL165562A0 (de)
MX (1) MXPA04012396A (de)
NO (1) NO20050141L (de)
OA (1) OA12867A (de)
PE (1) PE20040563A1 (de)
PL (1) PL373085A1 (de)
TW (1) TW200307544A (de)
WO (2) WO2003106429A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437869T1 (de) 2004-04-28 2009-08-15 Hetero Drugs Ltd Verfahren zur herstellung von pyridinylmethyl-1h- benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
EP2275088B2 (de) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Verfahren zur Granulatherstellung
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2016172436A1 (en) * 2015-04-23 2016-10-27 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles and polymers thereof as antimicrobial agents and methods using same
IL283809B2 (en) 2016-06-21 2024-01-01 Univ Columbia Compounds for use in a method of treating neuropathy, retinopathy, nephropathy, or cardiomyopathy
US11111216B2 (en) 2016-10-26 2021-09-07 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents and methods using same
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
AU2020254610A1 (en) 2019-04-01 2021-11-18 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
KR20210156235A (ko) * 2020-06-17 2021-12-24 일동제약(주) 신규한 산 분비 억제제 및 이의 용도
IT202200001022A1 (it) * 2022-01-21 2023-07-21 Exo Lab Italia Composti farmaceutici ibridi ottenuti mediante coniugazione di un inibitore delle pompe protoniche e un inibitore delle anidrasi carboniche
CN120590773B (zh) * 2025-08-06 2025-12-26 广州仕天材料科技有限公司 一种增强型聚碳酸酯和制备方法及在汽车照明系统中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
KR890000387B1 (ko) 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
AU3659200A (en) * 1999-04-09 2000-11-14 Basf Aktiengesellschaft Prodrugs of thrombin inhibitors
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
EP1334971A4 (de) 2000-10-12 2004-05-12 Takeda Chemical Industries Ltd Benzimidazolverbindungen, verfahren zu deren herstellung und deren verwendung
US7087600B2 (en) * 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
US20040248941A1 (en) 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof

Also Published As

Publication number Publication date
PL373085A1 (en) 2005-08-08
AR040221A1 (es) 2005-03-16
BR0311801A (pt) 2005-04-12
US20060293371A1 (en) 2006-12-28
DE60328603D1 (de) 2009-09-10
OA12867A (en) 2006-09-15
AU2003242388A1 (en) 2003-12-31
NO20050141D0 (no) 2005-01-11
WO2003105845A1 (en) 2003-12-24
CA2489470A1 (en) 2003-12-24
AU2003242390A1 (en) 2003-12-31
MXPA04012396A (es) 2005-06-17
TW200307544A (en) 2003-12-16
NO20050141L (no) 2005-01-27
KR20050009751A (ko) 2005-01-25
EP1513527A1 (de) 2005-03-16
EP1514870A1 (de) 2005-03-16
WO2003106429A1 (ja) 2003-12-24
CN1678315A (zh) 2005-10-05
JPWO2003106429A1 (ja) 2005-10-13
EP1514870A4 (de) 2006-08-23
EP1513527B1 (de) 2009-07-29
CA2489361A1 (en) 2003-12-24
PE20040563A1 (es) 2004-10-21
US20050222210A1 (en) 2005-10-06
US7410981B2 (en) 2008-08-12
IL165562A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE60331479D1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
TW200510333A (en) Benzimidazole compounds
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE361296T1 (de) Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid) 2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
NO20075764L (no) Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE602004011946D1 (de) Alkalisalze von protonenpumpen-hemmern
IL164735A0 (en) Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
EA200701852A1 (ru) Производные аминокислот
MY140194A (en) Novel fusidic acid derivatives
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties